To objectively investigate retinal function deterioration due to the inflammatory process by ERG. To investigate if risk factors for loss of ERG activity in uveitis herald more aggressive immunomodulation treatment to prevent visual loss.
ID
Source
Brief title
Condition
- Eye disorders
- Autoimmune disorders
- Hepatobiliary neoplasms malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The retinal function measured by ERG is the main outcome of the study. ERG
reduction, reflecting retinal damage, will be analysed throughout the course of
uveitis. ERGs will be evaluated on several parameters, including a and b wave
amplitude, latency, waveform, b:a wave ratio, and oscillatory potentials.
Secondary outcome
- When ERG reduction, reflecting retinal damage, occurs in the course of
uveitis.
- To which extent different forms of uveitis, i.e. anterior, intermediate,
posterior, panuveitis or specific diagnosis influence ERG abnormalities
- To which extent clinical parameters, including demographics, treatment and
ophthalmologic examination results (e.g. visual acuity, severity of
inflammation scored according to the SUN criteria18, flare, presence of CME,
retinal vasculitis or chorioiditis on FA, OCT values and visual fields)
influence ERG abnormalities.
- To which extent ERG abnormalities are reversible.
Background summary
Uveitis is a major cause of severe visual impairment. It is often of a chronic
nature and is treatable with steroids and other immudolatory drugs. However, a
series of severe complications can occur. Several studies have objectivized the
retinal damage which can occur due to ocular inflammation in certain forms of
uveitis by measuring full field electroretinogram (ffERG). If electroretinogram
( ERG) changes can predict early subclinical tissue damage, it is a helpful
tool to monitor patients for the treatment of uveitis. Since ERG abnormalities
in uveitis might be irreversible, deterioration of ERG might indicate more
aggressive treatment strategies with immunomodulating agents early in the
disease process. Furthermore, knowledge about functional aspects of the retina
measured by ERG in uveitis, can give insight in the pathogenesis of tissue
damage in the course of the disease.
Study objective
To objectively investigate retinal function deterioration due to the
inflammatory process by ERG. To investigate if risk factors for loss of ERG
activity in uveitis herald more aggressive immunomodulation treatment to
prevent visual loss.
Study design
Observational, cohort study.
Study burden and risks
The performance of an ERG takes up to 30 minutes to an hour. It is a
non-painful, non-invasive test. The risks associated with an ERG are
negligible.
Heidelberglaan 100
Utrecht 3584 CX
NL
Heidelberglaan 100
Utrecht 3584 CX
NL
Listed location countries
Age
Inclusion criteria
Age *18 years
Diagnosed with uveitis
Mentally competent
Exclusion criteria
Patients who do not speak or understand the Dutch language will be excluded from participation in this study.
Age *18 years
Patients with a family history of retinal dystrophy.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL56732.041.16 |